Document Detail

Protease inhibitor use in 233 pregnancies.
MedLine Citation:
PMID:  16123678     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: In the United States, as most highly active antiretroviral therapy (HAART) regimens used during pregnancy in HIV-infected women include a protease inhibitor (PI), it is important to determine the effects of PIs specifically rather than all HAART regimens. Prospective trials employing HAART during pregnancy are ongoing. OBJECTIVE: To better understand the effects of PI use during pregnancy on prematurity, maternal and infant adverse events, and infant outcomes. RESULTS: A total of 233 pregnancies in which PIs were used were reported, including 5 sets of twins and 1 set of triplets. Perinatal transmission is documented in 2 of 221 infants for a rate of 0.9% (95% CI, 0%-2.2%). Both HIV-positive infants were delivered by cesarean section (one elective at 37 1/7 weeks and one unscheduled at 32 6/7 weeks). The prematurity rate (<37 weeks' gestation) was 22.0% (95% CI, 16.9%-28.0%) including 3 twin and 1 triplet pregnancies. In multiple regression analysis no association was noted for individual PIs or the week of gestation that PIs were initiated. Adverse maternal, obstetric, and infant events possibly related to PIs were uncommon. CONCLUSIONS: In this series, PIs during pregnancy appeared generally safe for mothers and infants. Perinatal transmission was low and the prematurity rate is similar to prior data in HIV-positive women not on PIs.
Anne B Morris; Ana Rua Dobles; Susan Cu-Uvin; Carmen Zorrilla; Jean Anderson; Joseph I Harwell; Jean Keller; Jane Garb
Related Documents :
23440828 - Human chorionic gonadotrophin (hcg) for preventing miscarriage.
10325298 - Trisomy 2 in an acardiac twin in a triplet in-vitro fertilization pregnancy.
15925058 - Fetal reduction in a nontuplet pregnancy: technical and ethical considerations.
7900508 - Perinatal outcome after in vitro fertilisation.
24976478 - Managing cardiovascular disease during pregnancy: best practice to optimize outcomes.
21388678 - Villous trophoblast abnormalities in extremely preterm deliveries with elevated second ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of acquired immune deficiency syndromes (1999)     Volume:  40     ISSN:  1525-4135     ISO Abbreviation:  J. Acquir. Immune Defic. Syndr.     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2005-08-26     Completed Date:  2005-11-02     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  100892005     Medline TA:  J Acquir Immune Defic Syndr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  30-3     Citation Subset:  IM; X    
Community Research Initiative of New England, Springfield, MA 01107, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
CD4 Lymphocyte Count
Cesarean Section
Cohort Studies
HIV / isolation & purification
HIV Infections / drug therapy*,  immunology,  prevention & control*,  transmission,  virology
Infant, Newborn
Infectious Disease Transmission, Vertical / prevention & control*
Pregnancy Complications, Infectious / drug therapy*,  immunology,  prevention & control*,  virology
Premature Birth
Protease Inhibitors / administration & dosage*
Retrospective Studies
Treatment Outcome
Viral Load
Reg. No./Substance:
0/Protease Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after sin...
Next Document:  HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with det...